Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.55 |
| ▸ | CCND1 | P24385 | 17/20 | 0.55 |
| ▸ | CCND2 | P30279 | 17/20 | 0.55 |
| ▸ | CCND3 | P30281 | 17/20 | 0.55 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.53 |
| ▸ | MARK3 | P27448 | 1/20 | 0.53 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.53 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.53 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.53 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24654535 | 0.99 | CDK4 (0.57) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL22557889 | 0.99 | CDK4 (0.53) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL28902349 | 0.95 | CDK4 (0.49) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL30030223 | 0.95 | CDK4 (0.49) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL24654482 | 0.89 | CDK4 (0.53) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL24654479 | 0.87 | CDK4 (0.44) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL27393299 | 0.86 | CDK4 (0.57) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL22553641 | 0.85 | CCND1 (0.41) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL30031119 | 0.83 | CDK4 (0.44) | CDK4CCND1CCND2CCND3NUAK1 | |
| SCHEMBL31664302 | 0.82 | CDK4 (0.41) | CDK4CCND1CCND2CCND3NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119715833-A | Method for detecting related substances in par Bai Xi or salt thereof | 北京斯利安药业有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-116283969-B | Process for preparing palbociclib and related intermediates thereof | 杭州新曦科技有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-116283969-A | Process for preparing palbociclib and related intermediates thereof | 杭州新曦科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-112661753-B | Preparation method of palbociclib intermediate | 山东铂源药业股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114437066-A | Preparation method of palbociclib intermediate | 重庆市碚圣医药科技股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-113999227-A | Preparation method of palbociclib intermediate | 常州大学 | 2022-02-01 | — | — | CN | claimed |
| CN-112898299-B | Preparation method of palbociclib intermediate | 山东铂源药业有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-112898299-A | Preparation method of palbociclib intermediate | 山东铂源药业有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-112661753-A | Preparation method of palbociclib intermediate | 山东铂源药业有限公司 | 2021-04-16 | — | — | CN | claimed |
| CN-111423437-B | Preparation method of palbociclib intermediate | 天津法莫西医药科技有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-111423437-A | Preparation method of palbociclib intermediate | 天津法莫西医药科技有限公司 | 2020-07-17 | — | — | CN | claimed |
| CN-107903259-B | Preparation method of palbociclib intermediate | 浙江工业大学 | 2020-03-17 | — | — | CN | claimed |
| US-20250388576-A1 | PYRIDONOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF | UNIV EAST CHINA NORMAL (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4588917-A1 | PYRIDONOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF | East China Normal University (CN) | 2025-07-23 | — | — | EP | disclosed |
| CN-119715833-A | Method for detecting related substances in par Bai Xi or salt thereof | 北京斯利安药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-116283969-B | Process for preparing palbociclib and related intermediates thereof | 杭州新曦科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20080125588-A1 | SYNTHESIS OF 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-d] PRYIMIDIN-7-ONES | PFIZER INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125588-A1 | SYNTHESIS OF 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-d] PRYIMIDIN-7-ONES | PFIZER INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008032157-A2 | SYNTHESIS OF 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032157-A2 | SYNTHESIS OF 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125588-A1 | SYNTHESIS OF 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-d] PRYIMIDIN-7-ONES | DPYD, PIR, PLK2 | CDK4 62/4885CCND1 48/4885CCND2 56/4885 |
| US-20250388576-A1 | PYRIDONOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF | RPS6KA1, RPS6KA3, RPS6KA5 | CDK4 609/4885CCND1 2533/4885CCND2 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.